CLN3 is required for the clearance of glycerophosphodiesters from lysosomes

A new study shows CLN3, a lysosomal transmembrane protein, is required for the lysosomal clearance of glycerophospholipid and that glycerophosphoinositol is a disease biomarker for Batten disease. Great work to advance lysosomal storage disorder treatments from a team from Stanford UniversityThe National Institutes of HealthLeibniz Institute on Aging – Fritz Lipmann Institute (FLI)Ludwig-Maximilians-Universität MünchenWhitehead Institute for Biomedical ResearchUniversity of Virginia School of Medicine and David Sabatini!

Full article on

carbohyde blog, rare disease

ZyVersa Therapeutics and Larkspur health acquisition corp. announce business combination, interim financing, and pipe investment update

A little business for today:
ZyVersa Therapeutics Inc., a clinical-stage specialty biopharmaceutical company developing, among others, a cyclodextrin drug candidate (VAR 200), announced an aggregate committed financing in support of the business combination at $10.0 million.
This investment will enable Zyversa to advance clinical evaluation of the cholesterol efflux mediator candidate (VAR 200) in patients with orphan renal disease, FSGS, and to progress into Phase 1 trials – said Steve Glover and Daniel J. O’Connor
Read more on the ZyVersa website

Synthesis, binding affinity, and inhibitory capacity of cyclodextrin-based multivalent glycan ligands for human galectin-3

Bathing in carbs: Lai-Xi Wang and his group from the University of Maryland reported the synthesis of cyclodextrin-based multivalent glycan ligands for human galectin-3. The GalNAc (Tn antigen) containing heptavalent ligand showed the highest affinity for human Gal-3 among the synthetic ligands tested, with an EC50 of 1.4 μM in binding to human Gal-3.

Link to the article

carbohyde, galectin, cyclodextrin